FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982168466> ?p ?o ?g. }

• W2982168466 abstract "Abstract Background The prognosis of cancer patients has been improved partly because of the progress in cancer therapy, which increases the cancer survivors in the society. It may raise a concern regarding the development of heart failure (HF), because the anticancer agents have some serious side effects on cardiovascular system, especially in the aging society including Japan. However, the epidemiological data for the risk of HF in the cancer survivors is limited due to the lack of comprehensive dataset in the aging society. In this regard, the electronic health record (EHR), a big data, from the National Health Insurance in Japan provides a unique opportunity to obtain the suitable dataset. Purpose The purpose of this study was to clarify the prevalence and the risk factors of HF in cancer survivors, focusing on the impact of their age, using EHR in Japan. Methods We examined the EHR of 17.8 million patients, covering 14% of the total Japanese population. The EHR includes the diagnoses as coded with International Classification of Diseases, 10th revision (ICD-10), and the information for therapeutics. We extracted 159,380 patients who received anticancer agents between April 2008 to January 2017. HF patients were identified accordingto ICD-10 codes and the record for the use of therapeutic drugs for HF at least once after the HF diagnosis following the treatment with anticancer agents. We excluded the patients if they had other conditions indistinguishable from HF or if they had past history of HF before receiving anticancer agents. Results The mean follow-up period was 1.75 years and mean age (standard deviation) was 68.9 (11.6) years. The population over 75 years old were 37%, while males were 59.5%. There were prostate cancer (28.1%), lung cancer (13.4%), and colon cancer (12.6%)in males, and breast cancer (42.8%), colon cancer (11.5%), and lung cancer (8.6%)in females. Among them, 5,529 patients were diagnosed with HF, corresponding to the prevalence of 3.8%. The mean time form the initiation of chemotherapy to the HF onset was 1.03 year. In the Cox's proportional hazard model after the adjustments for comorbidity, HF was more prevalent in males with hazard ratio (HR) 1.07 and 95% C.I. 1.01–1.13 (p<0.05) and in those with obesity (HR 1.18, 95% C.I. 1.09–1.26, p<0.01).We divided the subjects into three age groups (younger; <65 years, intermediate; 65–74 years, older; ≥75 years). HF was more prevalent in older group than younger group (HR 1.72, 95% C.I. 1.60–1.85, p<0.01). Among the anticancer agents, doxorubicin showed HR 2.09 (95% C.I. 1.89–2.3, p<0.01), and trastuzumab showed HR 1.47 (95% C.I 1.25–1.73, p<0.01). Conclusion We showed that the average prevalence of HF after anticancer agentwas 3.8%. The independent risk factors for HF were older age, male, obesity, and the use of doxorubicin or trastuzumab. This study also demonstrated the usefulness of EHR in Japan, to investigate the cardiovascular risk associated with the anticancer agents." @default.
• W2982168466 created "2019-11-01" @default.
• W2982168466 creator A5002691316 @default.
• W2982168466 creator A5003939480 @default.
• W2982168466 creator A5007051012 @default.
• W2982168466 creator A5012373197 @default.
• W2982168466 creator A5037302816 @default.
• W2982168466 creator A5048159513 @default.
• W2982168466 creator A5087888150 @default.
• W2982168466 date "2019-10-01" @default.
• W2982168466 modified "2023-09-27" @default.
• W2982168466 title "P3121Cancer therapeutics-related heart failure from a cohort study using big data of electronic health record in Japan" @default.
• W2982168466 doi "https://doi.org/10.1093/eurheartj/ehz745.0196" @default.
• W2982168466 hasPublicationYear "2019" @default.
• W2982168466 type Work @default.
• W2982168466 sameAs 2982168466 @default.
• W2982168466 citedByCount "0" @default.
• W2982168466 crossrefType "journal-article" @default.
• W2982168466 hasAuthorship W2982168466A5002691316 @default.
• W2982168466 hasAuthorship W2982168466A5003939480 @default.
• W2982168466 hasAuthorship W2982168466A5007051012 @default.
• W2982168466 hasAuthorship W2982168466A5012373197 @default.
• W2982168466 hasAuthorship W2982168466A5037302816 @default.
• W2982168466 hasAuthorship W2982168466A5048159513 @default.
• W2982168466 hasAuthorship W2982168466A5087888150 @default.
• W2982168466 hasConcept C124101348 @default.
• W2982168466 hasConcept C126322002 @default.
• W2982168466 hasConcept C160735492 @default.
• W2982168466 hasConcept C162324750 @default.
• W2982168466 hasConcept C194828623 @default.
• W2982168466 hasConcept C2778198053 @default.
• W2982168466 hasConcept C3018060332 @default.
• W2982168466 hasConcept C3019952477 @default.
• W2982168466 hasConcept C3020144179 @default.
• W2982168466 hasConcept C41008148 @default.
• W2982168466 hasConcept C50522688 @default.
• W2982168466 hasConcept C71924100 @default.
• W2982168466 hasConcept C72563966 @default.
• W2982168466 hasConcept C75684735 @default.
• W2982168466 hasConceptScore W2982168466C124101348 @default.
• W2982168466 hasConceptScore W2982168466C126322002 @default.
• W2982168466 hasConceptScore W2982168466C160735492 @default.
• W2982168466 hasConceptScore W2982168466C162324750 @default.
• W2982168466 hasConceptScore W2982168466C194828623 @default.
• W2982168466 hasConceptScore W2982168466C2778198053 @default.
• W2982168466 hasConceptScore W2982168466C3018060332 @default.
• W2982168466 hasConceptScore W2982168466C3019952477 @default.
• W2982168466 hasConceptScore W2982168466C3020144179 @default.
• W2982168466 hasConceptScore W2982168466C41008148 @default.
• W2982168466 hasConceptScore W2982168466C50522688 @default.
• W2982168466 hasConceptScore W2982168466C71924100 @default.
• W2982168466 hasConceptScore W2982168466C72563966 @default.
• W2982168466 hasConceptScore W2982168466C75684735 @default.
• W2982168466 hasLocation W29821684661 @default.
• W2982168466 hasOpenAccess W2982168466 @default.
• W2982168466 hasPrimaryLocation W29821684661 @default.
• W2982168466 hasRelatedWork W184563434 @default.
• W2982168466 hasRelatedWork W1965877608 @default.
• W2982168466 hasRelatedWork W1995331253 @default.
• W2982168466 hasRelatedWork W2145833871 @default.
• W2982168466 hasRelatedWork W2145974468 @default.
• W2982168466 hasRelatedWork W2165053958 @default.
• W2982168466 hasRelatedWork W2463247497 @default.
• W2982168466 hasRelatedWork W2473818349 @default.
• W2982168466 hasRelatedWork W2521076287 @default.
• W2982168466 hasRelatedWork W2566095867 @default.
• W2982168466 hasRelatedWork W2791726927 @default.
• W2982168466 hasRelatedWork W2905942061 @default.
• W2982168466 hasRelatedWork W2986901488 @default.
• W2982168466 hasRelatedWork W3011763212 @default.
• W2982168466 hasRelatedWork W3082542652 @default.
• W2982168466 hasRelatedWork W3090577677 @default.
• W2982168466 hasRelatedWork W3111503262 @default.
• W2982168466 hasRelatedWork W3186666776 @default.
• W2982168466 hasRelatedWork W3200959227 @default.
• W2982168466 hasRelatedWork W480761678 @default.
• W2982168466 isParatext "false" @default.
• W2982168466 isRetracted "false" @default.
• W2982168466 magId "2982168466" @default.
• W2982168466 workType "article" @default.